Literature DB >> 28344538

Surgical Excision of Mycosis Fungoides Using Thumb-Sparing Reconstruction.

Giancarlo McEvenue1, Ashley Kim1, Paul Binhammer2.   

Abstract

Background: The differential for soft tissue tumors of the hand and upper limb is broad. Hematologic malignancy remains quite low on the differential for soft tissue tumors involving the hand, and there is little in the literature describing surgical management of such cutaneous manifestations. When the tumor is large or involves the thumb, careful consideration of reconstructive options is required.
Methods: We present a rare case of an aggressively enlarging mycosis fungoides, a cutaneous T-cell lymphoma tumor, involving the thumb. This tumor had a history of multiple failed treatment attempts, including radiation and chemotherapy.
Results: Our surgical plan was a reverse radial forearm osteocutaneous flap.
Conclusion: A reverse radial osteocutaneous forearm flap was successfully used to avoid thumb amputation and preserve thumb function.

Entities:  

Keywords:  hand tumor; mycosis fungoides; radial forearm flap; thumb reconstruction; upper extremity

Mesh:

Year:  2016        PMID: 28344538      PMCID: PMC5349418          DOI: 10.1177/1558944716669085

Source DB:  PubMed          Journal:  Hand (N Y)        ISSN: 1558-9447


  11 in total

Review 1.  T-cell lymphoma of the upper eyelid: a case report and review of the literature.

Authors:  D J Verret; Robert J DeFatta; Yadranko Ducic
Journal:  Surg Oncol       Date:  2006-12-19       Impact factor: 3.279

2.  Osteocutaneous radial forearm flap for hand reconstruction.

Authors:  H Yajima; S Tamai; T Yamauchi; S Mizumoto
Journal:  J Hand Surg Am       Date:  1999-05       Impact factor: 2.230

3.  Reverse radial forearm fascial flap for soft tissue coverage of hand and forearm wounds.

Authors:  R A Rogachefsky; C G Mendietta; P Galpin; E A Ouellette
Journal:  J Hand Surg Br       Date:  2000-08

Review 4.  Primary cutaneous T-cell lymphoma: review and current concepts.

Authors:  R S Siegel; T Pandolfino; J Guitart; S Rosen; T M Kuzel
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

5.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

Authors:  Nita Sally Agar; Emma Wedgeworth; Siobhan Crichton; Tracey J Mitchell; Michael Cox; Silvia Ferreira; Alistair Robson; Eduardo Calonje; Catherine M Stefanato; Elizabeth Mary Wain; Bridget Wilkins; Paul A Fields; Alan Dean; Katherine Webb; Julia Scarisbrick; Stephen Morris; Sean J Whittaker
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

6.  Surgical treatment of obstructive palpebral tumors in d'emblee variant of cutaneous T-cell lymphoma.

Authors:  Anna D Guanche; Kimberly Bohjanen; Whitney D Tope
Journal:  Dermatol Surg       Date:  2004-12       Impact factor: 3.398

7.  Primary cutaneous B-cell lymphoma: Role of surgery.

Authors:  Sam Parbhakar; Arianna Dal Cin
Journal:  Can J Plast Surg       Date:  2011

Review 8.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

9.  Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology.

Authors:  M A Weinstock; J W Horm
Journal:  JAMA       Date:  1988-07-01       Impact factor: 56.272

10.  Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

Authors:  E Diamandidou; M Colome-Grimmer; L Fayad; M Duvic; R Kurzrock
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.